Browsing by Author "Dimitrijević, Bogomir (57192871567)"
Now showing 1 - 6 of 6
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Concomitant aberrant methylation of p15 and MGMT genes in acute myeloid leukemia: Association with a particular immunophenotype of blast cells(2012) ;Kraguljac Kurtović, Nada (37037758700) ;Krajnović, Milena (14056061500) ;Bogdanović, Andrija (6603686934) ;Suvajdžić, Nada (7003417452) ;Jovanović, Jelica (57202914654) ;Dimitrijević, Bogomir (57192871567) ;Čolović, Milica (21639151700)Krtolica, Koviljka (6602075155)In this study, methylation-specific polymerase chain reaction (MS-PCR) was used to define the methylation status of the target promoter sequences of p15 and MGMT genes in the group of 21 adult patients with acute myeloid leukemia (AML). The incidence of aberrant hypermethylation of p15 gene (71 %) was higher comparing to MGMT gene (33 %), whereas concomitant methylation of both genes had 24 % of the patients. Although the incidence of cytogenetic abnormalities between the groups with a different methylation status of p15 and/or MGMT genes was not significantly different, we observed general trend of clustering of abnormalities with adverse prognosis into groups with concomitant hypermethylation of both genes and only p15 gene. Also, we showed that AML patients with concomitant methylation of p15/MGMT genes had a higher proportion of leukemic blast cells characterized with specific expression of individual leukocyte surface antigens (CD117+/CD7+/CD34 +/CD15-), indicating leukemic cells as early myeloid progenitors. Although we could not prove that hypermethylation of p15 and/or MGMT genes is predictive parameter for response to therapy and overall survival, we noticed that AML patients with comethylated p15/MGMT genes or methylated p15 gene exhibited a higher frequency of early death, lower frequency of complete remissions as well as a trend for shorter overall survival. Assessing of the methylation status of p15 and MGMT genes may allow stratification of patients with AML into distinct groups with potentially different prognosis. © 2012 Springer Science+Business Media, LLC. - Some of the metrics are blocked by yourconsent settings
Publication Concomitant aberrant methylation of p15 and MGMT genes in acute myeloid leukemia: Association with a particular immunophenotype of blast cells(2012) ;Kraguljac Kurtović, Nada (37037758700) ;Krajnović, Milena (14056061500) ;Bogdanović, Andrija (6603686934) ;Suvajdžić, Nada (7003417452) ;Jovanović, Jelica (57202914654) ;Dimitrijević, Bogomir (57192871567) ;Čolović, Milica (21639151700)Krtolica, Koviljka (6602075155)In this study, methylation-specific polymerase chain reaction (MS-PCR) was used to define the methylation status of the target promoter sequences of p15 and MGMT genes in the group of 21 adult patients with acute myeloid leukemia (AML). The incidence of aberrant hypermethylation of p15 gene (71 %) was higher comparing to MGMT gene (33 %), whereas concomitant methylation of both genes had 24 % of the patients. Although the incidence of cytogenetic abnormalities between the groups with a different methylation status of p15 and/or MGMT genes was not significantly different, we observed general trend of clustering of abnormalities with adverse prognosis into groups with concomitant hypermethylation of both genes and only p15 gene. Also, we showed that AML patients with concomitant methylation of p15/MGMT genes had a higher proportion of leukemic blast cells characterized with specific expression of individual leukocyte surface antigens (CD117+/CD7+/CD34 +/CD15-), indicating leukemic cells as early myeloid progenitors. Although we could not prove that hypermethylation of p15 and/or MGMT genes is predictive parameter for response to therapy and overall survival, we noticed that AML patients with comethylated p15/MGMT genes or methylated p15 gene exhibited a higher frequency of early death, lower frequency of complete remissions as well as a trend for shorter overall survival. Assessing of the methylation status of p15 and MGMT genes may allow stratification of patients with AML into distinct groups with potentially different prognosis. © 2012 Springer Science+Business Media, LLC. - Some of the metrics are blocked by yourconsent settings
Publication P14ARF methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma(2013) ;Davidović, Radoslav (55376761400) ;Sopta, Jelena (24328547800) ;Mandušić, Vesna (16203425000) ;Krajnović, Milena (14056061500) ;Stanojević, Maja (57828665700) ;Tulić, Goran (23036995600)Dimitrijević, Bogomir (57192871567)Liposarcoma represents the most frequent group of soft tissue sarcomas. The group can be divided into three different classes: (1) differentiated/ undifferentiated (WDLPS/DDLPS), (2) myxoid/round cell (MLPS/RCLPS) and (3) pleomorphic liposarcoma (PLS). It has become apparent that p53-p14 and Rb-p16 pathways play important roles in the pathogenesis of various sarcoma types. Molecular studies of the genes involved in these two pathways showed wide variations between the liposarcoma subtypes or even within the same subtype. We sought to examine mutational status of p53 and methylation status of p16 INK4a/p14ARF genes in primary and recurrent liposarcoma tumors. There were twelve myxoid (12/18, 66.7 %) and six pleomorphic liposarcoma (6/18, 33.3 %) samples. Immunohistochemical analysis revealed that p53 protein was overexpressed in 3/12 MLPS (25 %) and 6/6 PLS (100 %). Mutational analysis showed that 2/11 MLPS (18.2 %) and 2/6 PLS (33.3 %) contained mutated p53 gene. On the other hand, 3/18 samples (16.7 %) had methylated p16 promoter. However, the frequencies of the p14ARF gene methylation were 83.3 % (10/12) and 50 % (3/6) in myxoid and pleomorphic group, respectively. Overall, 15 out of 18 (83.3 %) samples had either p53 gene mutation or methylated p14 ARF promoter. The results from the current study suggest significant impact of the p14ARF gene methylation on the pathogenesis and progression of myxoid and to a lesser extent pleomorphic liposarcoma. Despite the limited number of samples, our study points to necessity of further investigation of p53-p14 and Rb-p16 pathways in liposarcoma. © Springer Science+Business Media New York 2013. - Some of the metrics are blocked by yourconsent settings
Publication P14ARF methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma(2013) ;Davidović, Radoslav (55376761400) ;Sopta, Jelena (24328547800) ;Mandušić, Vesna (16203425000) ;Krajnović, Milena (14056061500) ;Stanojević, Maja (57828665700) ;Tulić, Goran (23036995600)Dimitrijević, Bogomir (57192871567)Liposarcoma represents the most frequent group of soft tissue sarcomas. The group can be divided into three different classes: (1) differentiated/ undifferentiated (WDLPS/DDLPS), (2) myxoid/round cell (MLPS/RCLPS) and (3) pleomorphic liposarcoma (PLS). It has become apparent that p53-p14 and Rb-p16 pathways play important roles in the pathogenesis of various sarcoma types. Molecular studies of the genes involved in these two pathways showed wide variations between the liposarcoma subtypes or even within the same subtype. We sought to examine mutational status of p53 and methylation status of p16 INK4a/p14ARF genes in primary and recurrent liposarcoma tumors. There were twelve myxoid (12/18, 66.7 %) and six pleomorphic liposarcoma (6/18, 33.3 %) samples. Immunohistochemical analysis revealed that p53 protein was overexpressed in 3/12 MLPS (25 %) and 6/6 PLS (100 %). Mutational analysis showed that 2/11 MLPS (18.2 %) and 2/6 PLS (33.3 %) contained mutated p53 gene. On the other hand, 3/18 samples (16.7 %) had methylated p16 promoter. However, the frequencies of the p14ARF gene methylation were 83.3 % (10/12) and 50 % (3/6) in myxoid and pleomorphic group, respectively. Overall, 15 out of 18 (83.3 %) samples had either p53 gene mutation or methylated p14 ARF promoter. The results from the current study suggest significant impact of the p14ARF gene methylation on the pathogenesis and progression of myxoid and to a lesser extent pleomorphic liposarcoma. Despite the limited number of samples, our study points to necessity of further investigation of p53-p14 and Rb-p16 pathways in liposarcoma. © Springer Science+Business Media New York 2013. - Some of the metrics are blocked by yourconsent settings
Publication Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma(2013) ;Krajnović, Milena (14056061500) ;Radojković, Milica (57197430605) ;Davidović, Radoslav (55376761400) ;Dimitrijević, Bogomir (57192871567)Krtolica, Koviljka (6602075155)In this study, methylation-specific polymerase chain reaction was used to investigate the role and potential prognostic significance of the methylation status of p16, p15, MGMT and DAPK genes in 32 specimens of follicular lymphoma (FL). Hypermethylation of p15 gene was associated with lower hemoglobin level (P = 0.020) and MGMT/DAPK comethylation with relapsed disease (P = 0.018). Among all patients with FL, there was no significant difference in the overall survival between those with hypermethylated and unmethylated of any examined genes. Therefore, we analyzed methylation in the different groups according to FL International Prognostic Index (FLIPI) and tumor grade. In the high-risk group, patients with hypermethylated p16 gene had significant lower overall survival than those with unmethylated p16 (P = 0.006) and trend toward shorter failure-free survival (P = 0.068). In the same risk group, there was a trend toward longer overall survival for patients with hypermethylated MGMT gene, compared to those with unmethylated MGMT gene (P = 0.066). p15 methylation had impact on shorter overall survival in grade I group of patients (P = 0.013), and DAPK methylation tended to have impact on shorter failure-free survival in the whole examined group (P = 0.079). Our results suggest that promoter methylation of p16 and MGMT genes could have prognostic value when used in combination with the FLIPI and p15 methylation in combination with tumor grade. Concurrent methylation of MGMT and DAPK genes could be the marker of tumor chemoresistance and disease recurrence. © 2012 Springer Science+Business Media New York. - Some of the metrics are blocked by yourconsent settings
Publication Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma(2013) ;Krajnović, Milena (14056061500) ;Radojković, Milica (57197430605) ;Davidović, Radoslav (55376761400) ;Dimitrijević, Bogomir (57192871567)Krtolica, Koviljka (6602075155)In this study, methylation-specific polymerase chain reaction was used to investigate the role and potential prognostic significance of the methylation status of p16, p15, MGMT and DAPK genes in 32 specimens of follicular lymphoma (FL). Hypermethylation of p15 gene was associated with lower hemoglobin level (P = 0.020) and MGMT/DAPK comethylation with relapsed disease (P = 0.018). Among all patients with FL, there was no significant difference in the overall survival between those with hypermethylated and unmethylated of any examined genes. Therefore, we analyzed methylation in the different groups according to FL International Prognostic Index (FLIPI) and tumor grade. In the high-risk group, patients with hypermethylated p16 gene had significant lower overall survival than those with unmethylated p16 (P = 0.006) and trend toward shorter failure-free survival (P = 0.068). In the same risk group, there was a trend toward longer overall survival for patients with hypermethylated MGMT gene, compared to those with unmethylated MGMT gene (P = 0.066). p15 methylation had impact on shorter overall survival in grade I group of patients (P = 0.013), and DAPK methylation tended to have impact on shorter failure-free survival in the whole examined group (P = 0.079). Our results suggest that promoter methylation of p16 and MGMT genes could have prognostic value when used in combination with the FLIPI and p15 methylation in combination with tumor grade. Concurrent methylation of MGMT and DAPK genes could be the marker of tumor chemoresistance and disease recurrence. © 2012 Springer Science+Business Media New York.
